Welcome to our dedicated page for Pulmatrix news (Ticker: PULM), a resource for investors and traders seeking the latest updates and insights on Pulmatrix stock.
Pulmatrix, Inc. develops inhaled therapeutic product candidates using its iSPERSE dry powder delivery technology for migraine and respiratory diseases. Company news centers on clinical and regulatory disclosures tied to programs such as PUR3100, PUR1800 and PUR1900, along with operating results, corporate updates and financing or capital-structure matters.
Recurring developments also include material agreements, shareholder voting matters and governance disclosures that relate to Pulmatrix's public-company status and biopharmaceutical development activities.
Pulmatrix (NASDAQ: PULM) announced the appointment of Todd Bazemore to its Board of Directors, effective October 1, 2020. Bazemore brings over 25 years of biopharmaceutical experience, particularly in respiratory and rare diseases, and has held significant roles at Kala Pharmaceuticals and Santhera Pharmaceuticals. CEO Ted Read expressed confidence in Bazemore's strategic guidance in advancing Pulmatrix's inhaled therapies aimed at serious pulmonary diseases. Pulmatrix is developing innovative therapies using its patented iSPERSE™ technology, targeting conditions such as allergic bronchopulmonary aspergillosis and lung cancer.
On September 22, 2020, Pulmatrix (NASDAQ: PULM) announced updates on its product pipeline amid challenges from COVID-19. The company raised over $30M in 2020 through partnerships and public financing, enabling progress on three key programs.
PUR1800 Phase 1b dosing aims for Q1 2021, potentially triggering a $2M milestone from Johnson & Johnson. PUR3100, targeting migraine, is expected to advance to Phase 1/1b in Q1 2022. The Pulmazole Phase 2 study was halted due to COVID-19, with plans for a larger Phase 2b study once conditions improve.
Pulmatrix, Inc. (NASDAQ: PULM) reports its Q2 2020 financial results, highlighting key advancements in its partnerships and product development. The company anticipates a commercial launch of FEND, an OTC nasal hygiene product, in fall 2020, which could generate significant royalty revenues. A Phase 2 clinical study of Pulmazole was halted to pave the way for a new Phase 2b study starting in Q3 2021. As of June 30, 2020, Pulmatrix held $27.3 million in cash, down from $4.8 million in Q2 2019 revenue performance, with an ongoing net loss of $1.2 million in Q2 2020.